Cargando…

CRS + HIPEC combined with IP + IV chemotherapy for gastric signet-ring cell carcinoma: Case report of long-term survival

RATIONALE: Signet ring cell carcinoma of the stomach is prone to relapse and metastasis after traditional surgical treatment, and the prognosis is also poor. We improved the concept of treatment and conducted cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) combined...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yan, Guo-Jun, Ji, Zhong-He, Liu, Gang, Li, Yan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2020
Materias:	4500
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7544424/ https://www.ncbi.nlm.nih.gov/pubmed/33031325 http://dx.doi.org/10.1097/MD.0000000000022647

Ejemplares similares

Retrospective Analysis of Patients with Signet Ring Subtype of Colorectal Cancer with Peritoneal Metastasis Treated with CRS & HIPEC
por: Prabhu, Aruna, et al.
Publicado: (2020)

Signet ring cell carcinoma of early gastric cancer, is endoscopic treatment really risky?
por: Kang, Sun Hyung, et al.
Publicado: (2017)

Development and validation of a predictive model associated with lymph node metastasis of gastric signet ring carcinoma patients
por: Wang, Wei, et al.
Publicado: (2023)

A nomogram for the prediction of survival for colorectal signet ring cell carcinoma after surgery: A population-based study
por: Zhou, Di, et al.
Publicado: (2023)

The characteristics and prognostic value of signet ring cell histology in gastric cancer: A retrospective cohort study of 2199 consecutive patients
por: Lu, Ming, et al.
Publicado: (2016)

Signet Ring Cell Histology Is Not an Independent Predictor of Poor Prognosis After Curative Resection for Gastric Cancer: A Propensity Analysis by the KLASS Group
por: Shim, Jung Ho, et al.
Publicado: (2014)

Large tumor size is a poor prognostic factor of gastric cancer with signet ring cell: Results from the surveillance, epidemiology, and end results database
por: Zhou, Liyuan, et al.
Publicado: (2019)

Etiological analysis of infection after CRS + HIPEC in patients with PMP
por: Yang, Rui, et al.
Publicado: (2023)

Impact of insurance status on overall survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC)
por: Chokshi, Ravi J., et al.
Publicado: (2020)

Treatment of hypermyoglobinemia after CRS + HIPEC for patients with peritoneal carcinomatosis: A retrospective comparative study
por: Liu, Gang, et al.
Publicado: (2017)

Long-term progression-free survival of hepatocellular carcinoma with synchronous diffuse peritoneal metastasis treated by CRS+HIPEC: A case report and literature review
por: Ji, Zhong-He, et al.
Publicado: (2019)

The use of Hypotension Prediction Index in cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC)
por: Gangakhedkar, Gauri R., et al.
Publicado: (2022)

Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis
por: Vassos, Nikolaos, et al.
Publicado: (2016)

Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): a Single-Center Experience in Austria
por: Pamela, Kogler, et al.
Publicado: (2018)

Initial Experience of Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Baltic Country Center
por: Račkauskas, Rokas, et al.
Publicado: (2022)

A Meta-analysis Reveals S-1-based Chemotherapy Improves the Survival of Patients With Advanced Gastric Cancer
por: Wu, Fang-Lan, et al.
Publicado: (2015)

Critical Analysis of Stage IV Epithelial Ovarian Cancer Patients after Treatment with Neoadjuvant Chemotherapy followed by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC)
por: Munoz-Zuluaga, Carlos A., et al.
Publicado: (2020)

Immature enteric ganglion cells were observed in a 13-year-old colon signet ring cell carcinoma patient: A case report and literature review
por: Li, Huili, et al.
Publicado: (2017)

Immune profile of patients with peritoneal carcinomatosis selected for CRS-HIPEC therapy
por: Kleber, Julia, et al.
Publicado: (2023)

Serum procalcitonin improves diagnosis of infectious complications after CRS/HIPEC
por: Roth, Lilian, et al.
Publicado: (2023)

The impact of urological resection and reconstruction on patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)
por: Tan, Grace Hwei Ching, et al.
Publicado: (2018)

Cytoreductive Surgery (CRS) and Hyperthermic IntraPeritoneal Chemotherapy (HIPEC): don’t throw the baby out with the bathwater
por: Königsrainer, Alfred, et al.
Publicado: (2018)

Reply to: “Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Definitively Does Not Deserve Its Bad Reputation”
por: Horvath, Philipp, et al.
Publicado: (2021)

Early postoperative CRP predicts major complications following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)
por: Kartik, Akash, et al.
Publicado: (2023)

Postoperative pain pathophysiology and treatment strategies after CRS + HIPEC for peritoneal cancer
por: Wang, Xiao, et al.
Publicado: (2020)

Anesthetic management of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC): The importance of hydro-electrolytic and acid-basic control
por: Mendonça, Fabrício Tavares, et al.
Publicado: (2017)

The prognosis impact of hyperthermic intraperitoneal chemotherapy (HIPEC) plus cytoreductive surgery (CRS) in advanced ovarian cancer: the meta-analysis
por: Zhang, Guyu, et al.
Publicado: (2019)

Current Trends in Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Disease from Appendiceal and Colorectal Malignancies
por: Harper, Megan M., et al.
Publicado: (2022)

Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in small bowel adenocarcinoma with peritoneal metastasis: a systematic review
por: Chen, Vicky, et al.
Publicado: (2022)

Comprehensive evaluation of clinical efficacy and safety of celecoxib combined with chemotherapy in management of gastric cancer
por: Guo, Qinghong, et al.
Publicado: (2017)

CRS and HIPEC in patients with peritoneal metastasis secondary to colorectal cancer: The small-bowel PCI score as a predictor of survival
por: Spiliotis, John, et al.
Publicado: (2019)

The efficacy and feasibility of adopting intravenous chemotherapy and oral S-1 as a sequential therapy for postoperative gastric cancer patients
por: Yan, Long, et al.
Publicado: (2019)

Enhanced recovery after surgery (ERAS) in cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): a cross-sectional survey
por: Bhandoria, Geetu, et al.
Publicado: (2021)

Survival benefit of palliative gastrectomy followed by chemotherapy in stage IV gastric signet ring cell carcinoma patients: A large population‐based study
por: Shi, Tao, et al.
Publicado: (2019)

Pancreatic carcinosarcoma with rare long-term survival: Case report and review of the literature
por: Jia, Zhe, et al.
Publicado: (2017)

Long-Term Survival Following Pancreatectomy and S-1 Chemotherapy for Pancreatic Acinar Cell Carcinoma With Peritoneal Dissemination: A Case Report and Literature Review
por: Sumiyoshi, Tatsuaki, et al.
Publicado: (2015)

Can baseline quality of life scores predict for morbidity and survival after CRS and HIPEC: a prospective study of 151 patients
por: Chia, Claramae Shulyn, et al.
Publicado: (2022)

Cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) vs CRS alone for treatment of endometrial cancer with peritoneal metastases: a multi-institutional study from PSOGI and BIG RENAPE groups
por: Gomes David, Manuel, et al.
Publicado: (2022)

Society of Onco-Anaesthesia and Perioperative Care consensus guidelines for perioperative management of patients for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC)
por: Solanki, Sohan Lal, et al.
Publicado: (2019)

Durable Response after Repeat Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in a Patient with Extensive Mucinous Adenocarcinoma of the Appendix
por: Kaakour, Dalia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5tevlr2vb3lb1e567f9usimlbd